Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma

Ronald M. Bukowski, James Young, Gary Goodman, Frederick J Meyers, Brian F. Issell, James S. Sergi, Denise McLain, Gwen Fyfe, James Finke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recombinant interleukin-2 (rIL-2) modified with monomethoxypolyethylene glycol (PEG IL-2) was utilized in patients with metastatic renal cell carcinoma in two separate multi-institutional trials. PEG IL-2 was administered as an I.V. bolus days 1, 8, 15, and 22 with cycles repeated every six weeks. The two trials employed different dose levels: A) 20x106 I.U./m2 day 1 followed by 12x106 I.U./m2 days 8, 15, 22; and B) 12x106 I.U./m2 days 1, 8, 15, 22. Thirty-five patients were entered and 31 were evaluable for response (A-15/18, B-16/17). Two of 31 patients had partial responses. Median therapy duration was four weeks (range 1-15), and dose reduction for grade III or IV toxicity was required in 14/35 patients (A-6/18, B-8/17). Toxicity (≥ grade III) seen included: hypotension 51%, dyspnea 17%, seizures 6%, and mental status changes 11%. No differences in response or toxicity between the two schedules were noted. Hematologic changes included lymphocytosis and eosinophilia in the majority of patients. PEG IL-2 given once weekly has significant toxicity, and may produce tumor regression in patients with renal cell carinoma.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalInvestigational New Drugs
Volume11
Issue number2-3
DOIs
StatePublished - Jun 1993

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Lymphocytosis
Eosinophilia
Dyspnea
Hypotension
Appointments and Schedules
Seizures
Kidney
polyethylene glycol-modified interleukin-2
Neoplasms

Keywords

  • PEG IL-2
  • phase II trial
  • renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Polyethylene glycol conjugated interleukin-2 : Clinical and immunologic effects in patients with advanced renal cell carcinoma. / Bukowski, Ronald M.; Young, James; Goodman, Gary; Meyers, Frederick J; Issell, Brian F.; Sergi, James S.; McLain, Denise; Fyfe, Gwen; Finke, James.

In: Investigational New Drugs, Vol. 11, No. 2-3, 06.1993, p. 211-217.

Research output: Contribution to journalArticle

Bukowski, RM, Young, J, Goodman, G, Meyers, FJ, Issell, BF, Sergi, JS, McLain, D, Fyfe, G & Finke, J 1993, 'Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma', Investigational New Drugs, vol. 11, no. 2-3, pp. 211-217. https://doi.org/10.1007/BF00874158
Bukowski, Ronald M. ; Young, James ; Goodman, Gary ; Meyers, Frederick J ; Issell, Brian F. ; Sergi, James S. ; McLain, Denise ; Fyfe, Gwen ; Finke, James. / Polyethylene glycol conjugated interleukin-2 : Clinical and immunologic effects in patients with advanced renal cell carcinoma. In: Investigational New Drugs. 1993 ; Vol. 11, No. 2-3. pp. 211-217.
@article{0a5b4c3240004b8ba4ed51a594060bc5,
title = "Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma",
abstract = "Recombinant interleukin-2 (rIL-2) modified with monomethoxypolyethylene glycol (PEG IL-2) was utilized in patients with metastatic renal cell carcinoma in two separate multi-institutional trials. PEG IL-2 was administered as an I.V. bolus days 1, 8, 15, and 22 with cycles repeated every six weeks. The two trials employed different dose levels: A) 20x106 I.U./m2 day 1 followed by 12x106 I.U./m2 days 8, 15, 22; and B) 12x106 I.U./m2 days 1, 8, 15, 22. Thirty-five patients were entered and 31 were evaluable for response (A-15/18, B-16/17). Two of 31 patients had partial responses. Median therapy duration was four weeks (range 1-15), and dose reduction for grade III or IV toxicity was required in 14/35 patients (A-6/18, B-8/17). Toxicity (≥ grade III) seen included: hypotension 51{\%}, dyspnea 17{\%}, seizures 6{\%}, and mental status changes 11{\%}. No differences in response or toxicity between the two schedules were noted. Hematologic changes included lymphocytosis and eosinophilia in the majority of patients. PEG IL-2 given once weekly has significant toxicity, and may produce tumor regression in patients with renal cell carinoma.",
keywords = "PEG IL-2, phase II trial, renal cell carcinoma",
author = "Bukowski, {Ronald M.} and James Young and Gary Goodman and Meyers, {Frederick J} and Issell, {Brian F.} and Sergi, {James S.} and Denise McLain and Gwen Fyfe and James Finke",
year = "1993",
month = "6",
doi = "10.1007/BF00874158",
language = "English (US)",
volume = "11",
pages = "211--217",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2-3",

}

TY - JOUR

T1 - Polyethylene glycol conjugated interleukin-2

T2 - Clinical and immunologic effects in patients with advanced renal cell carcinoma

AU - Bukowski, Ronald M.

AU - Young, James

AU - Goodman, Gary

AU - Meyers, Frederick J

AU - Issell, Brian F.

AU - Sergi, James S.

AU - McLain, Denise

AU - Fyfe, Gwen

AU - Finke, James

PY - 1993/6

Y1 - 1993/6

N2 - Recombinant interleukin-2 (rIL-2) modified with monomethoxypolyethylene glycol (PEG IL-2) was utilized in patients with metastatic renal cell carcinoma in two separate multi-institutional trials. PEG IL-2 was administered as an I.V. bolus days 1, 8, 15, and 22 with cycles repeated every six weeks. The two trials employed different dose levels: A) 20x106 I.U./m2 day 1 followed by 12x106 I.U./m2 days 8, 15, 22; and B) 12x106 I.U./m2 days 1, 8, 15, 22. Thirty-five patients were entered and 31 were evaluable for response (A-15/18, B-16/17). Two of 31 patients had partial responses. Median therapy duration was four weeks (range 1-15), and dose reduction for grade III or IV toxicity was required in 14/35 patients (A-6/18, B-8/17). Toxicity (≥ grade III) seen included: hypotension 51%, dyspnea 17%, seizures 6%, and mental status changes 11%. No differences in response or toxicity between the two schedules were noted. Hematologic changes included lymphocytosis and eosinophilia in the majority of patients. PEG IL-2 given once weekly has significant toxicity, and may produce tumor regression in patients with renal cell carinoma.

AB - Recombinant interleukin-2 (rIL-2) modified with monomethoxypolyethylene glycol (PEG IL-2) was utilized in patients with metastatic renal cell carcinoma in two separate multi-institutional trials. PEG IL-2 was administered as an I.V. bolus days 1, 8, 15, and 22 with cycles repeated every six weeks. The two trials employed different dose levels: A) 20x106 I.U./m2 day 1 followed by 12x106 I.U./m2 days 8, 15, 22; and B) 12x106 I.U./m2 days 1, 8, 15, 22. Thirty-five patients were entered and 31 were evaluable for response (A-15/18, B-16/17). Two of 31 patients had partial responses. Median therapy duration was four weeks (range 1-15), and dose reduction for grade III or IV toxicity was required in 14/35 patients (A-6/18, B-8/17). Toxicity (≥ grade III) seen included: hypotension 51%, dyspnea 17%, seizures 6%, and mental status changes 11%. No differences in response or toxicity between the two schedules were noted. Hematologic changes included lymphocytosis and eosinophilia in the majority of patients. PEG IL-2 given once weekly has significant toxicity, and may produce tumor regression in patients with renal cell carinoma.

KW - PEG IL-2

KW - phase II trial

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027244915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027244915&partnerID=8YFLogxK

U2 - 10.1007/BF00874158

DO - 10.1007/BF00874158

M3 - Article

C2 - 8262734

AN - SCOPUS:0027244915

VL - 11

SP - 211

EP - 217

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2-3

ER -